We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Biologic monotherapy in the treatment of rheumatoid arthritis.
- Authors
Detert, Jacqueline; Klaus, Pascal
- Abstract
Biologics, possibly in combination with a conventional disease-modifying antirheumatic drug (DMARD) - preferably methotrexate (MTX), are used in accordance with the recommendations of the international rheumatological societies. However, in clinical practice, this recommendation is often problematic, as many rheumatologists know from personal experience. The quality of life of the patient is affected mainly by drug-induced intolerances (eg, MTX). Thus, the acceptance of the patient to treatment is often so inadequate that a discontinuation of the drug is necessary. In daily practice, approximately 30% of patients with biological therapy receive no concomitant DMARD according to the register data.
- Subjects
BIOTHERAPY; RHEUMATOID arthritis treatment; METHOTREXATE; ANTIRHEUMATIC agents; QUALITY of life; DRUG efficacy; AUTOIMMUNE disease treatment
- Publication
Biologics: Targets & Therapy, 2015, Vol 9, p35
- ISSN
1177-5475
- Publication type
Article
- DOI
10.2147/BTT.S53361